Beam Therapeutics CEO on CRISPR’s future, sickle cell research: The Endpoints Slack interview - Endpoints News
endpts.comSubmitted by endpointsnews6292 in health
Even with last year's landmark approvals for genetic medicines in sickle cell disease, John Evans is convinced his startup can push the field further. Beam Therapeutics started 2024 by announcing it had dosed the first sickle cell patient with its base-editin…